GLP-1 Insurance Coverage in 2026: What's Changed and What to Expect

Medicare's GLP-1 Bridge launches July 1, 2026 with $50/month copays. Medicaid states are joining through the CMS BALANCE Model. Commercial plans are slowly expanding. Complete coverage landscape.

The biggest barrier to brand-name GLP-1 access has always been cost. In 2026, the coverage landscape is shifting — slowly, unevenly, but meaningfully — in the patient's favor.

Medicare: The Bridge Program

The most significant development: Medicare's GLP-1 Bridge program launches July 1, 2026. Key provisions:

• $50/month copay for covered GLP-1 medications (Wegovy, Zepbound KwikPen, and Foundayo)
• Available to Medicare Part D enrollees who meet obesity criteria
• Prior authorization required — expect documentation of BMI, comorbidities, and previous weight management attempts
• Coverage is for the obesity indication specifically — diabetes indication GLP-1 coverage under Part D has existed separately

This is transformative for the 65+ population. Prior to the Bridge program, most Medicare Part D plans excluded weight-loss medications entirely. The $50 copay makes brand-name GLP-1 therapy accessible to millions of seniors for the first time.

Medicaid: The BALANCE Model

The CMS BALANCE Model is expanding GLP-1 coverage to participating Medicaid states. As of May 2026:

• Multiple states have joined or announced intent to join the model
• Coverage criteria vary by state but generally follow the FDA-label BMI requirements
• The model includes outcomes tracking requirements — states must demonstrate cost-effectiveness to maintain coverage

Commercial Insurance: Uneven Progress

Commercial plan coverage remains a patchwork. The general trend through 2026:

• Large employer plans: Approximately 40–50% now cover at least one GLP-1 for obesity (up from ~25% in 2024)
• Step therapy requirements: Many plans require documented failure of lifestyle modification and/or metformin before approving GLP-1 therapy
• Prior authorization: Near-universal for obesity indication. Typical requirements: BMI documentation, comorbidity list, physician attestation of medical necessity
• Preferred drug lists: Plans increasingly require specific GLP-1 brands (often Wegovy or Zepbound, not both) — switching from the non-preferred to preferred agent is common

The Prior Authorization Playbook

For any insurance pathway, the prior authorization process is the bottleneck. Evidence-based strategies to improve approval odds:

• Document BMI at every visit — a single BMI reading is weaker than a trend
• List all comorbidities explicitly: hypertension, T2D, sleep apnea, NAFLD, osteoarthritis, PCOS — each strengthens the case
• Document prior weight management attempts: diet programs, exercise regimens, nutritional counseling. The more documented history, the better
• Use peer-to-peer review: If initially denied, request a peer-to-peer conversation between your physician and the insurance medical reviewer. Approval rates increase significantly at this stage
• Appeal denials: First-level appeals overturn approximately 40–50% of initial denials for GLP-1 prior authorizations

When Compounded Makes More Sense Than Insurance

Even with improving coverage, many patients find the compounded pathway faster and simpler:

• No prior authorization process (typically 2-4 weeks for brand-name)
• No step therapy requirements
• Compounded semaglutide from $99/month vs. variable copays of $50-500/month for brand-name
• Some providers, like Found Health, offer both pathways — insurance coordination for brand-name and compounded backup if insurance is denied